The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No intervention measures.
- Who it may be relevant to
- Registry conditions: Anxiety/Depression and Asthma. Basic parameters: from 14 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety/depression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions. Participants will: Complete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety/depression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up
Interventions
- Other No intervention measures
No intervention measures
Primary outcome measures
- Acute asthma attack [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria.
- Male or female patients aged 14 years or older.
- Complete clinical data available.
- Newly diagnosed asthma or stable asthma.
- Receiving asthma controller medication.
Exclusion criteria
- History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery.
- Incomplete medical records.
- Cognitive impairment or inability to complete psychological scale assessments.
- Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia.
- Current use of antidepressant or anti-anxiety medications.
- Pregnancy or lactation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Xiangya Hospital Central South University — Changsha
Identifiers
NCT: NCT07679321 · XiangyaHr